Jacobs Levy Equity Management’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-97,379
| Closed | -$810K | – | 933 |
|
|
2024
Q3 | $810K | Sell |
97,379
-189,881
| -66% | -$1.58M | ﹤0.01% | 765 |
|
|
2024
Q2 | $1.82M | Sell |
287,260
-57,988
| -17% | -$368K | 0.01% | 620 |
|
|
2024
Q1 | $2.09M | Sell |
345,248
-54,985
| -14% | -$333K | 0.01% | 591 |
|
|
2023
Q4 | $2.43M | Buy |
400,233
+300,832
| +303% | +$1.83M | 0.01% | 572 |
|
|
2023
Q3 | $419K | Buy |
99,401
+71,975
| +262% | +$304K | ﹤0.01% | 835 |
|
|
2023
Q2 | $85K | Sell |
27,426
-1,953,020
| -99% | -$6.05M | ﹤0.01% | 950 |
|
|
2023
Q1 | $2.75M | Buy |
1,980,446
+278,411
| +16% | +$387K | 0.02% | 519 |
|
|
2022
Q4 | $3.39M | Buy |
1,702,035
+259,725
| +18% | +$517K | 0.02% | 462 |
|
|
2022
Q3 | $2.91M | Sell |
1,442,310
-81,866
| -5% | -$165K | 0.02% | 486 |
|
|
2022
Q2 | $4.85M | Sell |
1,524,176
-63,780
| -4% | -$203K | 0.04% | 426 |
|
|
2022
Q1 | $6.62M | Sell |
1,587,956
-113,101
| -7% | -$472K | 0.04% | 369 |
|
|
2021
Q4 | $8.15M | Sell |
1,701,057
-181,129
| -10% | -$868K | 0.05% | 343 |
|
|
2021
Q3 | $10.1M | Sell |
1,882,186
-217,748
| -10% | -$1.16M | 0.07% | 296 |
|
|
2021
Q2 | $10.8M | Buy |
2,099,934
+436,882
| +26% | +$2.24M | 0.07% | 277 |
|
|
2021
Q1 | $11.2M | Buy |
1,663,052
+948,233
| +133% | +$6.38M | 0.09% | 270 |
|
|
2020
Q4 | $3.27M | Buy |
714,819
+414,546
| +138% | +$1.89M | 0.03% | 479 |
|
|
2020
Q3 | $1.17M | Buy |
300,273
+230,224
| +329% | +$893K | 0.01% | 628 |
|
|
2020
Q2 | $333K | Sell |
70,049
-177,725
| -72% | -$845K | ﹤0.01% | 867 |
|
|
2020
Q1 | $862K | Buy |
+247,774
| New | +$862K | 0.01% | 661 |
|
|
2019
Q4 | – | Sell |
-200,600
| Closed | -$582K | – | 993 |
|
|
2019
Q3 | $582K | Buy |
200,600
+165,800
| +476% | +$481K | 0.01% | 698 |
|
|
2019
Q2 | $250K | Buy |
+34,800
| New | +$250K | ﹤0.01% | 843 |
|